source
- Eli Lilly to acquire Merida Biosciences in up to $2.9 billion deal for precision antibody-degrading therapiesEli Lilly announced it will purchase Massachusetts‑based Merida Biosciences, adding a platform that can selectively degrade disease‑causing antibodies. The transaction could total up to $2.875 bil…
- Novartis and Bristol Myers pause autoimmune CAR-T trials after safety concernsNovartis announced a temporary hold on its personalized CAR-T therapy rap-cel after three patients experienced immune effector cell-associated hemophagocytic syndrome, a rare and potentially life-t…